[go: up one dir, main page]

MXPA05008524A - Pirazoles y metodos de elaboracion y uso de los mismos. - Google Patents

Pirazoles y metodos de elaboracion y uso de los mismos.

Info

Publication number
MXPA05008524A
MXPA05008524A MXPA05008524A MXPA05008524A MXPA05008524A MX PA05008524 A MXPA05008524 A MX PA05008524A MX PA05008524 A MXPA05008524 A MX PA05008524A MX PA05008524 A MXPA05008524 A MX PA05008524A MX PA05008524 A MXPA05008524 A MX PA05008524A
Authority
MX
Mexico
Prior art keywords
pyrazoles
making
methods
same
alk
Prior art date
Application number
MXPA05008524A
Other languages
English (en)
Inventor
Ling Leona
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MXPA05008524A publication Critical patent/MXPA05008524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se basa en el descubrimiento de que compuestos de formula I poseen inesperadamente alta afinidad para Alk 5 y/o Alk 4, y pueden ser utiles como antagonistas de los mismos para prevenir y/o tratar enfermedades numerosas, que incluyen trastornos fibroticos. En una modalidad, la invencion caracteriza un compuesto de formula I (I).
MXPA05008524A 2003-02-12 2004-02-12 Pirazoles y metodos de elaboracion y uso de los mismos. MXPA05008524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44677703P 2003-02-12 2003-02-12
PCT/US2004/004049 WO2004072033A2 (en) 2003-02-12 2004-02-12 Pyrazoles and methods of making and using the same

Publications (1)

Publication Number Publication Date
MXPA05008524A true MXPA05008524A (es) 2005-10-20

Family

ID=32869552

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008524A MXPA05008524A (es) 2003-02-12 2004-02-12 Pirazoles y metodos de elaboracion y uso de los mismos.

Country Status (21)

Country Link
US (1) US20060264440A1 (es)
EP (1) EP1596656A4 (es)
JP (1) JP2006517592A (es)
KR (1) KR20050101547A (es)
CN (1) CN1770980A (es)
AR (1) AR043184A1 (es)
AU (1) AU2004210855A1 (es)
BR (1) BRPI0407454A (es)
CA (1) CA2514382A1 (es)
CL (1) CL2004000234A1 (es)
EA (1) EA010161B1 (es)
GE (1) GEP20084391B (es)
IS (1) IS7966A (es)
MX (1) MXPA05008524A (es)
NO (1) NO20054200L (es)
NZ (1) NZ542289A (es)
PL (1) PL378072A1 (es)
RS (1) RS20050616A (es)
UA (1) UA82223C2 (es)
WO (1) WO2004072033A2 (es)
ZA (1) ZA200506408B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
AU2005238270A1 (en) * 2004-04-28 2005-11-10 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2005280167A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
WO2006044509A2 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
GB0520475D0 (en) * 2005-10-07 2005-11-16 Arrow Therapeutics Ltd Chemical compounds
KR20080083139A (ko) * 2006-01-11 2008-09-16 애로우 쎄라퓨틱스 리미티드 항-바이러스제로 사용하기 위한트리아졸로아닐리노피리미딘 유도체
CA2645583A1 (en) 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
CN101062916B (zh) * 2006-04-29 2012-12-26 中国人民解放军军事医学科学院毒物药物研究所 三取代1h-吡唑化合物、其制备方法、药物组合物及其制药用途
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090258882A1 (en) * 2006-07-28 2009-10-15 Novartis Ag 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
CA2666603C (en) * 2006-10-16 2013-08-06 Pfizer Products Inc. Therapeutic pyrazolyl thienopyridines and uses thereof for treating tgf.beta. mediated conditions
JP5507045B2 (ja) 2006-12-15 2014-05-28 石原産業株式会社 アントラニルアミド系化合物の製造方法
WO2009009059A1 (en) * 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
JP4792126B2 (ja) * 2007-08-01 2011-10-12 ファイザー・インク ピラゾール化合物およびＲａｆ阻害剤としてのその使用
CL2009000904A1 (es) 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
RU2615130C2 (ru) 2009-10-06 2017-04-04 Милленниум Фармасьютикалз, Инк Гетероциклические соединения, используемые в качестве ингибиторов pdk1
PL2647629T3 (pl) * 2010-12-01 2015-12-31 Nissan Chemical Ind Ltd Związki pirazolowe o terapeutycznym działaniu na szpiczaka mnogiego
KR101084729B1 (ko) 2011-06-10 2011-11-22 재단법인 한국원자력의학원 이소옥사졸 유도체를 포함하는 ＴＧＦ-β 활성 저해용 조성물
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013178591A1 (en) * 2012-05-31 2013-12-05 F. Hoffmann-La Roche Ag Aminoquinazoline and pyridopyrimidine derivatives
CN104487438B (zh) * 2012-07-26 2016-10-19 霍夫曼-拉罗奇有限公司 神经发生的苯并异噁唑调节剂
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
EP3722297A1 (en) 2015-03-04 2020-10-14 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP6954932B2 (ja) * 2016-06-13 2021-10-27 ジェンフリート セラピューティクス（シャンハイ）インコーポレイテッド ＴＧＦ−βＲＩ阻害剤としてのベンゾトリアゾール由来のα、β−不飽和アミド系化合物
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
ES2906581T3 (es) 2016-09-02 2022-04-19 Gilead Sciences Inc Compuestos moduladores de los receptores tipo Toll
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
AU2017357333A1 (en) * 2016-11-14 2019-05-02 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020215094A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
MX2022003769A (es) * 2019-10-03 2022-04-20 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas.
WO2021102468A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
MX2022005843A (es) 2019-11-28 2022-07-19 Agomab Spain S L U Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN113620956B (zh) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法
AU2022237836B2 (en) * 2021-03-18 2024-07-04 F. Hoffmann-La Roche Ag Process for preparing risdiplam
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) * 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
DE4233713A1 (de) * 1992-10-07 1994-04-14 Bayer Ag Substituierte 4,5-Dihydro-1-pyrazolcarbonsäureanilide
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5854276A (en) * 1995-06-29 1998-12-29 Fujisawa Pharmaceutical Co., Ltd. Substance WF16616, process for production thereof, and use thereof
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
BR9706973A (pt) * 1996-01-11 1999-04-06 Smithkline Beecham Corp Novos compostos de imidazol substituídos
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5939557A (en) * 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) * 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5854265A (en) * 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
DE69733135T2 (de) * 1996-06-10 2006-03-02 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
US5854264A (en) * 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9713027A (pt) * 1996-11-12 2000-01-25 Novartis Ag Derivados de pirazol úteis como herbicidas
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU7138298A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
WO2002048115A2 (en) * 2000-12-11 2002-06-20 E. I. Du Pont De Nemours And Company Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests
EP1363904A1 (en) * 2001-02-02 2003-11-26 Glaxo Group Limited Pyrazoles as tgf inhibitors
WO2002066462A1 (en) * 2001-02-02 2002-08-29 Glaxo Group Limited Pyrazole derivatives against tgf overexpression
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
DE10113000A1 (de) * 2001-03-17 2002-09-19 Bayerische Motoren Werke Ag System aus Verbrennungsmotor und Brennstoffzelle
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
PT1397364E (pt) * 2001-05-24 2007-10-22 Lilly Co Eli Novos derivados de pirrole como agentes farmacêuticos
ES2319972T3 (es) * 2001-10-15 2009-05-18 E.I. Du Pont De Nemours And Company Iminobenzoxazinas, iminobenzotiazinas e iminoquinazolinas para controlar plagas de invertebrados.
AR040726A1 (es) * 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EA200500377A1 (ru) * 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
EP1596656A2 (en) 2005-11-23
NO20054200D0 (no) 2005-09-09
NO20054200L (no) 2005-10-14
PL378072A1 (pl) 2006-02-20
AR043184A1 (es) 2005-07-20
NZ542289A (en) 2009-03-31
GEP20084391B (en) 2008-06-10
CL2004000234A1 (es) 2005-04-15
JP2006517592A (ja) 2006-07-27
UA82223C2 (uk) 2008-03-25
EP1596656A4 (en) 2006-10-18
IS7966A (is) 2005-07-29
KR20050101547A (ko) 2005-10-24
BRPI0407454A (pt) 2006-01-24
CN1770980A (zh) 2006-05-10
RS20050616A (sr) 2007-09-21
CA2514382A1 (en) 2004-08-26
WO2004072033A2 (en) 2004-08-26
EA200501274A1 (ru) 2006-02-24
WO2004072033A3 (en) 2005-03-17
EA010161B1 (ru) 2008-06-30
AU2004210855A1 (en) 2004-08-26
ZA200506408B (en) 2006-05-31
US20060264440A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
MXPA05002443A (es) Pirazolopiridinas y metodos para elaboracion y uso de las mismas.
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
AU2003281213A1 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
MY135841A (en) Novel benzodioxoles
GB0325956D0 (en) Novel compounds
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
DE602004018637D1 (de) A2a-adenosinrezeptorantagonisten
WO2004091514A3 (en) Cgrp receptor antagonists
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
DE60324544D1 (de) Muskarin antagonisten
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
GB0114185D0 (en) Compounds
MY141011A (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
MXPA02009549A (es) Imidazopiridinas triciclicas.